Research programme: selective androgen receptor modulators - Orion

Drug Profile

Research programme: selective androgen receptor modulators - Orion

Alternative Names: Arcarine; ORM-11984

Latest Information Update: 10 Aug 2011

Price : $50

At a glance

  • Originator Orion
  • Class
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Andropause; Benign prostatic hyperplasia; Hypogonadism; Osteoporosis; Prostate cancer

Most Recent Events

  • 02 Aug 2011 Preclinical development is ongoing in Finland
  • 15 Sep 2009 Preclinical pharmacodynamics data presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2009) ,,
  • 23 Jul 2007 Preclinical trials in Prostate cancer in Finland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top